Merck & CompanyvsPuma Biotechnology

MRK and PBYI stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$132.81

Value $328B

-3.61%
MRK's page

PBYI

Puma Biotechnology Inc

$7.12

Value $362M

-1.39%
PBYI's page

Merck & Company (MRK) has a market value of $328B and Puma Biotechnology (PBYI) $362M. Over the last year, with dividends, MRK moved +41.8% and PBYI +40.7%. The P/E is 133.9 for MRK and 15.2 for PBYI. Dividend yield: MRK 2.56%, PBYI none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$328B

    PBYI$362M

    MRK is 906 times PBYI

  • Revenue, 12 months

    MRK$67.4B

    PBYI$232M

    MRK is 291 times PBYI

  • Net income, 12 months

    MRK$2.5B

    PBYI$24M

    MRK is 103 times PBYI

  • Operating margin

    MRK–

    PBYI11.3%

  • ROIC

    MRK3.9%

    PBYI12.8%

    8.9 points apart

  • P/E

    MRK133.9

    PBYI15.2

    MRK is 8.8 times PBYI

  • Dividend yield

    MRK2.6%

    PBYI0.0%

    2.6 points apart

  • 5-year return

    MRK+86.3%

    PBYI+111.3%

    25.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+86.3%

PBYI+111.4%

10020030020222023202420252026
Returns by period
PeriodMRKWith dividendsPBYIWith dividends
1 year since November 18, 2025+41.8%Price +37.7%+40.7%Price +40.7%
3 years since November 17, 2023+43.1%+12.7% a yearPrice +30.5%+84.9%+22.7% a yearPrice +84.9%
5 years since November 18, 2021+86.3%+13.2% a yearPrice +59.9%+111.3%+16.1% a yearPrice +111.3%
10 years since November 21, 2016+203.1%+11.7% a yearPrice +123.4%-83.7%-16.6% a yearPrice -83.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanyPBYIPuma Biotechnology

Valuation

MRKPBYI
Valuation
Price$132.81$7.12
Market value$328B$362M
Enterprise value (EV)$372B$307M
P/E133.915.2
P/E, 5-year median14.89.6
P/B7.32.5
EV/EBIT78.211.7
Free cash flow yield4.5%12.7%

Results and growth

MRKPBYI
Results and growth
Revenue, 12 months$67.4B$232M
Net income, 12 months$2.5B$24M
Free cash flow, 12 months$14.7B$46M
Earnings per share, 12 months$0.98$0.46
Revenue growth, year on year1.3%-0.9%
Revenue growth a year, past+9.4%over 5 years+0.3%over 5 years
EPS growth a year, past+21.2%over 5 years–

Margins and returns on capital

MRKPBYI
Margins and returns on capital
Gross margin71.8%73.6%
Operating margin–11.3%
Net margin3.6%10.3%
ROIC3.9%12.8%
ROE5.2%18.1%

Balance sheet

MRKPBYI
Balance sheet
Cash$9.7B$101M
Total debt$53.8B$50M
Net debt / EBITDA5.7-1.5
Interest cover2.4×12.9×

Dividends and buybacks

MRKPBYI
Dividends and buybacks
Dividend yield2.6%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.6%–
Shareholder yield4.1%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or PBYI

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or Puma Biotechnology?

By market value, Merck & Company ($328B) is about 906.5 times Puma Biotechnology ($362M), at today's prices.

How did MRK and PBYI stock do over the last 10 years?

Since November 21, 2016, MRK's price moved +123.4% and PBYI's -83.7%. With dividends: MRK +203.1% (+11.7% a year), PBYI -83.7% (-16.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or PBYI?

The dividend yield at today's price is 2.56% for Merck & Company and none for Puma Biotechnology. Over the last twelve months they paid $3.40 and – per share.

What is the P/E of MRK and PBYI?

At today's price, the P/E is 133.9 for MRK and 15.2 for PBYI. The median of the last five years was 14.8 and 9.6, which shows where each stands against its own past.

Which has the higher profit margins, Merck & Company or Puma Biotechnology?

Over the last twelve months, the net margin was 3.6% for Merck & Company and 10.3% for Puma Biotechnology, and the operating margin – and 11.3%. Revenue was $67.4B and $232M.

Which is the better investment, Merck & Company or Puma Biotechnology?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.